Seaport Therapeutics and Hemab Therapeutics each launched initial public offerings on Thursday, collectively raising $556 million. The dual debut extends a robust run for biotech IPOs in 2025, which have now raised nearly $3.2 billion year-to-date.
Seaport, a clinical-stage neuroscience company, priced its IPO at $18 per share, selling 14.4 million shares to raise roughly $259 million. Hemab, focused on hematology therapies, offered 12.5 million shares at $24 each, bringing in approximately $297 million.
Both companies began trading on the Nasdaq under the tickers SEPR and HEMB, respectively. The pair joins more than a dozen other biotech IPOs this year, as investor appetite for novel drug developers continues to strengthen amid a favorable regulatory backdrop and advancing pipelines.
Hemab's lead candidate targets rare bleeding disorders, while Seaport's pipeline includes a late-stage treatment for major depressive disorder. Analysts view the successful pricing as a signal of renewed confidence in biotech financing, though the sector remains sensitive to clinical trial outcomes and drug pricing policy shifts.
Counter_argument: The biotech IPO market remains selective, and not all debuting companies have fared well post-listing—some have traded below their offering price, suggesting investor caution around valuation and pipeline risk.
aio_context: This brief was composed from a single source (BioPharma Dive) and reflects only the details reported in that article. No additional market data or company fundamentals were included beyond what the source provided.